The Latest Breaking News from Vertex

The award-winning creative director is a guest at Vertex 2024.

Vertex is the IBD Stock Of The Day. VRTX stock bounced off its 50-day line as investors watch for the first sales of its gene-editing drug.

Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.

The Ghostbusters concept artist will be at Vertex 2024.

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….

The stock market rally hit fresh highs, with the S&P 500 hit 5,000. Arm and Palantir skyrocketed, with several other AI plays running higher.

Vertex could bolster its cystic fibrosis franchise with a next-generation drug, analysts said Tuesday. But VRTX stock dipped.

Vertex's alternative to opioids is "not a game-changer," an analyst said Tuesday. But VRTX stock rebounded on the company's test results.

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

Vertex is the IBD Stock Of The Day as the maker of corporate tax compliance software expands its footprint with an acquisition.

Explore the cutting-edge research of three Breakthrough Prize laureates in Life Sciences, and the systemic issues that influence access to treatments for three diseases desperately looking for cures: Parkinson’s disease, cystic fibrosis, and cancer.